Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: Approach to subtyping progressive disease and clinical implications

Clinical Lung Cancer

Volumn 15, Issue 1, 2014, Pages 1-6

  Gandara, David R ^a   Li, Tianhong ^a   Lara, Primo N ^a   Kelly, Karen ^a   Riess, Jonathan W ^a   Redman, Mary W ^b   Mack, Philip C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARCINOMATOUS MENINGITIS; CLINICAL DECISION MAKING; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; LUNG NON SMALL CELL CANCER; ONCOGENE; REVIEW; STEREOTACTIC BODY RADIATION THERAPY;

CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; ONCOGENES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84891829967     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.10.001     Document Type: Note

References (36)

1. M. Imielinski, A.H. Berger, and P.S. Hammerman et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing Cell 150 2012 1107 1120
2. The Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancer Nature 489 2012 519 525
3. S. Roychowdhury, M.K. Iyer, and D.R. Robinson et al. Personalized oncology through integrative high-throughput sequencing: a pilot study Sci Transl Med 3 2011 111ra121
4. T. Li, H.-J. Kung, and P.C. Mack et al. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies J Clin Oncol 31 2013 1039 1049
5. T.J. Lynch, D.W. Bell, and R. Sordella et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
6. E.L. Kwak, Y.-J. Bang, and R. Camidge et al. Anaplastic lymphoma kinase Inhibition in non-small-cell lung cancer N Eng J Med 363 2010 1693 1703
7. J. Gainor, and A. Shaw Novel targets in non-small cell lung cancer: ROS1 and RET fusions Oncologist 18 2013 865 875
8. T.S. Mok, Y.L. Wu, and S. Thongprasert et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
9. T. Mitsudomi, Satoshi Morita, and Yasushi Yatabe et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
10. R. Rosell, E. Carcereny, and R. Gervais et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
11. M. Maemondo, A. Inoue, and K. Kobayashi et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
12. C.H. Yang, M.H. Schuler, and N. Yamamoto et al. LUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations J Clin Oncol 30 2012 abstract LBA7500
13. A.T. Shaw, D.-W. Kim, and K. Nakagawa et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 2013 2385 2394
14. R. Rosell, N. Karachaliou, and D. Morales- Espinosa et al. Adaptive resistance to targeted therapies in cancer Transl Lung Cancer Res 2 2013 152 159
15. D.R. Gandara, T. Li, and P.N. Lara Jr. et al. Algorithm for co-development of new drug-predictive biomarker combinations: accounting for inter- and intra-patient tumor heterogeneity Clin Lung Cancer 13 2012 321 325
16. Y. Iwasa, and F. Michor Evolutionary dynamics of intratumor heterogeneity PLoS ONE 6 2011 e17866
17. D. Jackman, W. Pao, and G.J. Riely et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer J Clin Oncol 28 2010 357 360
18. R.C. Doebele, A.B. Pilling, and D. Aisner et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer Clin Cancer Res 18 2012 1472 1482
19. T. Shukuya, T. Takahashi, and T. Naito et al. Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure Lung Cancer 74 2011 457 461
20. D.R. Gomez, Y. Niibe, and J.Y. Chang Oligometastatic disease at presentation or recurrence for nonsmall cell lung cancer Pulm Med 2012 2012 396592
21. A.J. Weickhardt, B. Scheier, and J.M. Burke et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer J Thorac Oncol 7 2012 1807 1814
22. E.T. Browning, A.J. Weickhardt, and D.R. Camidge Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer J Thorac Oncol 8 2013 e21 e22
23. J.K. Salama, S.J. Chmura, and N. Mehta et al. An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease Clin Cancer Res 14 2008 5255 5259
24. R. Rosell, T. Moran, and C. Queralt et al. Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 2009 958 967
25. D.R. Gandara, P. Grimminger, and P.C. Mack et al. Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer J Thorac Oncol 5 2010 1933 1938
26. J.O. Lee, T.M. Kim, and S.-H. Lee et al. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer J Thorac. Oncol 6 2011 1474 1480
27. D.R. Camidge, S.A. Kono, and X. Lu et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed J Thorac Oncol 6 2011 774 780
28. D.R. Gandara, E. Huang, and S. Desai et al. Thymidylate synthase (TS) gene expression in patients with ALK positive non-small cell lung cancer (NSCLC): implications for therapy J Clin Oncol 30 suppl 2012 (abstract 7582)
29. D.R. Camidge, and R.C. Doebele Treating ALK-positive lung cancer - early successes and future challenges Nat Rev Clin Oncol 9 2012 268 277
30. W. Pao, V.A. Miller, and K.A. Politi et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 2005 e73
31. Y.Y. Janjigian, H.F. Groen, and L. Horn et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib and gefitinib J Clin Oncol 29 2011 (abstract 7525)
32. A. Shaw, and J.A. Engelman ALK in lung cancer: past, present, and future J Clin Oncol 31 2013 1105 1111
33. A.M. Davies, C. Ho, and L. Beckett et al. Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation J Thorac Oncol 4 2009 862 868
34. T. Li, P.N. Lara, and P.C. Mack et al. Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer Current Drug Targets 11 2010 85 94
35. Y.-L. Wu, J.S. Lee, and S. Thongprasert et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial Lancet Oncol 14 2013 777 786
36. M.S. Cohen, Y.Q. Chen, and M. McCauley et al. Prevention of HIV-1 infection with early antiretroviral therapy N Engl J Med 365 2011 493 505